Associated tags: FDA, 3D, Patient, ECG, Food, Cardiology, Health, Medical Devices, Health Technology, Medical device, Doctor of Philosophy, Software, Biotechnology, Patent
Locations: TEXAS, VA, MASSACHUSETTS, BOSTON, SERBIA, SOUTH AFRICA, READING, UNITED STATES, NORTH AMERICA, CALIFORNIA, MOUNT SINAI, CORNERSTONE, US
Other Health,
General Health,
Hardware,
Biometrics,
Medical Devices,
Technology,
Artificial Intelligence,
Health Technology,
Cardiology,
Biotechnology,
Wearables,
Mobile Technology,
Health,
Patient,
Doctor of Philosophy,
Algorithm,
Atrial flutter,
Deep learning,
FDA,
Stroke,
Life,
MD,
Assistant,
AI,
VCG,
Medical director,
ECG,
Vectorcardiography,
Acquisition,
Machine learning,
Arrhythmia,
EP,
Medical device HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced new study data demonstrating that HeartBeam AI combined with vectorcardiography (VCG) outperformed an expert panel of heart rhythm cardiologists in detecting atrial flutter.
Key Points:
- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced new study data demonstrating that HeartBeam AI combined with vectorcardiography (VCG) outperformed an expert panel of heart rhythm cardiologists in detecting atrial flutter.
- HeartBeam AI is the company’s deep learning (a form of AI) algorithm for detecting abnormalities in the timing or pattern of heartbeats.
- In the study, HeartBeam AI was applied to a set of 173 VCGs, single-lead ECGs and 12-lead ECGs to identify atrial flutter.
- This study demonstrates that a deep learning algorithm applied to a transformed VCG performs comparably as well when applied to the gold-standard 12-lead ECG.
Cardiology,
General Health,
Health,
Artificial Intelligence,
Medical Devices,
Health Technology,
Technology,
Apps,
Applications,
Patient,
Doctor of Philosophy,
FDA,
Electronic health record,
Medical device,
Death,
EHR,
ECG,
Medtech,
Physician,
Telehealth HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that HeartBeam AIMIGo™ has been selected as winner of the “Best New ECG Technology Solution” award in the 8th annual MedTech Breakthrough Awards program.
Key Points:
- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that HeartBeam AIMIGo™ has been selected as winner of the “Best New ECG Technology Solution” award in the 8th annual MedTech Breakthrough Awards program.
- The awards program is conducted by MedTech Breakthrough , an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market.
- HeartBeam AIMIGo is a credit card-sized device for patient use at home or anywhere to facilitate remote evaluation of cardiac symptoms.
- HeartBeam believes this presents a unique opportunity to unlock a more personalized approach to cardiac care for patients.
Cardiology,
Software,
Health,
Artificial Intelligence,
Medical Devices,
Health Technology,
Technology,
Clinical Trials,
FDA,
Arrhythmia,
Vectorcardiography,
VCG,
Research,
United States patent law,
Doctor of Philosophy,
ECG,
Artificial intelligence,
Webcast,
3D,
Intelligence,
Consultant,
Atrial flutter,
Patient,
Patent,
Algorithm,
Medical device HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the first quarter ended March 31, 2024.
Key Points:
- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the first quarter ended March 31, 2024.
- Research and development expenses for the first quarter of 2024 were $2.4 million, compared to $1.7 million for the first quarter of 2023.
- General and administrative expenses for the first quarter of 2024 were $2.4 million compared to $2.5 million for the first quarter of 2023.
- Net loss for the first quarter of 2024 was $4.6 million, compared to a net loss of $4.1 million for the first quarter of 2023.
A press release detailing these results will be issued prior to the call.
Key Points:
- A press release detailing these results will be issued prior to the call.
- HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno, and Consulting CFO Richard Brounstein will host the conference call, followed by a question-and-answer period.
- The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company’s website here .
- To access the call, please use the following information:
Technology,
Medical Devices,
Health Technology,
Cardiology,
Software,
Biotechnology,
Health,
Data Management,
Artificial Intelligence,
Algorithm,
Atrial flutter,
Intelligence,
Patient,
Doctor of Philosophy,
MD,
Arrhythmia,
Vectorcardiography,
FDA,
VCG,
ECG,
Medical device This marks the first scientific presentation on the company’s deep learning algorithm, HeartBeam AI.
Key Points:
- This marks the first scientific presentation on the company’s deep learning algorithm, HeartBeam AI.
- The technology is designed to be used in HeartBeam’s small, portable, patient-friendly devices that allow for remote cardiac monitoring.
- HeartBeam believes this presents a unique opportunity to create a comprehensive repository of data that could unlock personalized AI-driven insights to improve cardiac care.
- “As we continue to expand our artificial intelligence capabilities, we look forward to demonstrating how the combination of our data rich 3D VECG platform with HeartBeam AI has the potential to transform how cardiac health is managed in the future.”
Retrieved on:
Wednesday, March 20, 2024
Cardiology,
Software,
Health,
Artificial Intelligence,
Medical Devices,
Health Technology,
Technology,
Clinical Trials,
Element,
Research,
Microsoft,
Algorithm,
Arrhythmia,
Apple,
Communication,
Patent,
Webcast,
Patient,
Lead,
Consultant,
Artificial intelligence,
G&A,
AI,
United States patent law,
Doctor of Philosophy,
Deep learning,
Abstract,
FDA,
ECG,
Medical device HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2023.
Key Points:
- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2023.
- Research and development expenses for the fourth quarter of 2023 were $2.0 million, compared to $1.6 million for the fourth quarter of 2022.
- General and administrative expenses for the fourth quarter of 2023 were $2.1 million compared to $2.1 million for the fourth quarter of 2022.
- Net loss for the fourth quarter of 2023 was $3.9 million, compared to a net loss of $3.7 million for the fourth quarter of 2022, and $14.6 million for the full year 2023 compared to $13.0 million in the same period of 2022.
Health,
FDA,
Medical Devices,
Health Technology,
Clinical Trials,
Cardiology,
Biotechnology,
Research,
Diagnosis,
FACC,
Electrophysiology,
Algorithm,
Arrhythmia,
Physician,
Patient,
Gold,
Doctor of Philosophy,
Deep learning,
ECG,
Medical device HeartBeam AIMIGo leverages HeartBeam’s proprietary 3D vectorelectrocardiography (3D VECG) technology to capture signals in three projections (X, Y, Z) and synthesize a 12-lead ECG.
Key Points:
- HeartBeam AIMIGo leverages HeartBeam’s proprietary 3D vectorelectrocardiography (3D VECG) technology to capture signals in three projections (X, Y, Z) and synthesize a 12-lead ECG.
- “We are thrilled to be part of this important study as AIMIGo represents a significant leap in cardiac monitoring technology.
- All patients enrolled in the study will receive simultaneously recorded ECGs from a standard 12-lead ECG machine and the HeartBeam AIMIGo system.
- The study will also examine the accuracy of physician diagnosis for various arrhythmias with the AIMIGo synthesized 12-lead ECG, compared to a standard 12-lead ECG.
Health Technology,
Health,
Cardiology,
Medical Devices,
Doctor of Philosophy,
AMI,
Physician,
Invention,
3D,
Patent,
AUC,
ECG,
Splenic infarction,
Patient,
Curve,
Heart,
Wrist,
Medical device HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has received two new patents on its core vectorelectrocardiography (VECG) technology from the United States Patent and Trademark Office.
Key Points:
- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has received two new patents on its core vectorelectrocardiography (VECG) technology from the United States Patent and Trademark Office.
- HeartBeam now has 14 issued and allowed US patents and 4 international patents for its VECG technology which collects 3D signals of the heart and converts them into a 12-lead ECG.
- For each patient, HeartBeam provides a comparative baseline ECG which aids physicians in gaining richer insights about the patient’s cardiac health.
- In addition to the 14 issued and allowed US patents and 4 international patents, HeartBeam has 20 pending applications worldwide.
A press release detailing these results will be issued prior to the call.
Key Points:
- A press release detailing these results will be issued prior to the call.
- HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno, Consulting CFO Richard Brounstein, and VP of Regulatory Affairs Deborah Castillo, PhD, will host the conference call, followed by a question-and-answer period.
- The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company’s website here .
- To access the call, please use the following information:
Retrieved on:
Thursday, December 14, 2023
Health,
Medical Devices,
Technology,
Health Technology,
Software,
Artificial Intelligence,
Biotechnology,
ECG,
Machine learning,
Verily,
Science,
Computational biology,
Algorithm,
Computer science,
Heart,
Artificial intelligence,
Map,
Biomedicine,
Heart failure,
University,
Apple,
3D,
Doctor of Philosophy,
Biomarker,
Physician,
Microsoft,
AI,
Biomedical engineering,
Automated ECG interpretation,
Medical device,
Medical imaging By coupling machine learning methods with the company’s VECG technology, HeartBeam aims to provide physicians with unprecedented diagnostic and prognostic insights about cardiac health that it believes will exceed the information provided by a standard 12-lead electrocardiogram (ECG).
Key Points:
- By coupling machine learning methods with the company’s VECG technology, HeartBeam aims to provide physicians with unprecedented diagnostic and prognostic insights about cardiac health that it believes will exceed the information provided by a standard 12-lead electrocardiogram (ECG).
- HeartBeam believes this presents a unique opportunity to create a comprehensive repository of data that could unlock personalized AI-driven insights to improve cardiac care.
- Additionally, Lance Myers, PhD, a pioneer in digital health data analytics and body-worn biosensor technologies, will be joining HeartBeam as Chief AI Advisor.
- “Having Mohammad and Lance join the company will be invaluable as we work towards our mission of transforming cardiac health.
